ClinicalTrials.gov
ClinicalTrials.gov Menu

Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02658279
Recruitment Status : Recruiting
First Posted : January 18, 2016
Last Update Posted : October 17, 2018
Sponsor:
Collaborators:
Merck Sharp & Dohme Corp.
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of California, San Francisco
Huntsman Cancer Institute/ University of Utah
University of California, Los Angeles
University of Miami
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : January 2019
  Estimated Study Completion Date : January 2019